These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745 [TBL] [Abstract][Full Text] [Related]
23. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Mahller YY; Rangwala F; Ratner N; Cripe TP Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003 [TBL] [Abstract][Full Text] [Related]
24. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Prabhakar S; Messerli SM; Stemmer-Rachamimov AO; Liu TC; Rabkin S; Martuza R; Breakefield XO Cancer Gene Ther; 2007 May; 14(5):460-7. PubMed ID: 17304235 [TBL] [Abstract][Full Text] [Related]
25. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Raki M; Hakkarainen T; Bauerschmitz GJ; Särkioja M; Desmond RA; Kanerva A; Hemminki A Gene Ther; 2007 Oct; 14(19):1380-8. PubMed ID: 17611584 [TBL] [Abstract][Full Text] [Related]
26. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024 [TBL] [Abstract][Full Text] [Related]
27. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531 [TBL] [Abstract][Full Text] [Related]
28. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
29. The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Colunga AG; Laing JM; Aurelian L Gene Ther; 2010 Mar; 17(3):315-27. PubMed ID: 19798049 [TBL] [Abstract][Full Text] [Related]
30. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515 [TBL] [Abstract][Full Text] [Related]
31. Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Kinoh H; Inoue M; Komaru A; Ueda Y; Hasegawa M; Yonemitsu Y Gene Ther; 2009 Mar; 16(3):392-403. PubMed ID: 19037241 [TBL] [Abstract][Full Text] [Related]
32. An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Griffith C; Noonan S; Lou E; Shillitoe EJ Cancer Gene Ther; 2007 Dec; 14(12):985-93. PubMed ID: 17853922 [TBL] [Abstract][Full Text] [Related]
33. E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. Wang G; Li G; Liu H; Yang C; Yang X; Jin J; Liu X; Qian Q; Qian W J Gene Med; 2009 Jun; 11(6):477-85. PubMed ID: 19340843 [TBL] [Abstract][Full Text] [Related]
34. Bovine herpesvirus type 1 as a novel oncolytic virus. Rodrigues R; Cuddington B; Mossman K Cancer Gene Ther; 2010 May; 17(5):344-55. PubMed ID: 19893594 [TBL] [Abstract][Full Text] [Related]
35. Suitability of a US3-inactivated HSV mutant (L1BR1) as an oncolytic virus for pancreatic cancer therapy. Kasuya H; Nishiyama Y; Nomoto S; Goshima F; Takeda S; Watanabe I; Nomura N; Shikano T; Fujii T; Kanazumi N; Nakao A Cancer Gene Ther; 2007 Jun; 14(6):533-42. PubMed ID: 17415379 [TBL] [Abstract][Full Text] [Related]
36. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196 [TBL] [Abstract][Full Text] [Related]
37. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models. Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615 [TBL] [Abstract][Full Text] [Related]
38. Vaccine potential of a herpes simplex virus type 2 mutant deleted in the PK domain of the large subunit of ribonucleotide reductase (ICP10). Aurelian L; Kokuba H; Smith CC Vaccine; 1999 Apr; 17(15-16):1951-63. PubMed ID: 10217594 [TBL] [Abstract][Full Text] [Related]
39. Combined oncolytic virotherapy with herpes simplex virus for oral squamous cell carcinoma. Ogawa F; Takaoka H; Iwai S; Aota K; Yura Y Anticancer Res; 2008; 28(6A):3637-45. PubMed ID: 19189645 [TBL] [Abstract][Full Text] [Related]
40. Reovirus - possible therapy of cancer. Figova K; Hrabeta J; Eckschlager T Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]